Dr. Ledermann on Rucaparib Maintenance in Ovarian Cancer
Jonathan Ledermann, MD
Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses rucaparib (Rubraca) maintenance in ovarian cancer.
The ARIEL3 trial is currently looking at maintenance therapy with rucaparib by giving patients chemotherapy, and then maintaining the response and freedom from progression by using a PARP inhibitor. Rucaparib is licensed in the United States for the treatment of BRCA-mutated ovarian cancer.
ARIEL3 is the third randomized trial in this setting.